Prosight Management discloses $42.7M GeneDx stake amid 30% share-price drop
What's the deal? Prosight ManagementDealroom has a profile for this one. Try Dealroom → has taken a major position in GeneDx Holdings, the genomic testing company. A Securities and Exchange Commission (SEC) filing on 15 May 2026 showed Prosight bought 468,463 shares valued at roughly $42.72 million, making GeneDx about 5.51% of the firm's reportable 13F assets under management.
Prosight isn't alone. GeneDx director Keith A. MeisterDealroom has a profile for this one. Try Dealroom → bought 351,273 shares in May 2026, and Meister's Corvex ManagementDealroom has a profile for this one. Try Dealroom → collectively acquired about $46.8 million of stock between 7 May and 11 May 2026.
Why now? GeneDx's stock was last quoted at $47.31, down roughly 30% between May 2025 and May 2026 — far behind the S&P 500's gain of about 28% over the same span. That gap may have created a buying opportunity for investors betting on a rebound.
The company's Q1 2026 results offered some encouragement. Revenue rose 17% year on year to $102.3 million. Exome and genome testing revenue climbed 27%, and testing volume jumped 34% to 27,488 tests. GeneDx ended 2025 with revenue of $427.5 million, up 41% from the prior year.
Management maintained its outlook for at least 30% growth in exome and genome volumes in 2026 and expects adjusted gross margins of about 70%. It also plans to broaden access to testing through expanded Medicaid coverage and new product launches.
What could go wrong? GeneDx trimmed its 2026 revenue guidance to between $475 million and $490 million, down from a previous range of $540 million to $555 million. That's a significant cut.
The company uses AI and machine learning to analyse clinical and genomic data through its Centrellis platform, but it operates in a market still trying to prove that rapid data growth can translate into sustained profits. A shrinking revenue forecast doesn't help that case.
The signal: GeneDx sits at the late growth stage according to Dealroom, a phase where the gap between rapid revenue expansion and consistent profitability typically narrows or widens decisively. The convergence of a corporate investor like Prosight and an investment fund like Corvex — two different investor archetypes — piling in during a 30% drawdown suggests the market may be mispricing GeneDx's transition from high-growth diagnostics platform to durable earnings generator. Whether the company's trimmed revenue guidance signals a temporary recalibration or a deeper structural challenge will likely determine if this coordinated bet pays off.
Read more: noah-news.com
